Results 341 to 350 of about 1,160,348 (369)
Some of the next articles are maybe not open access.
A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
, 2016 S. Ansell, Robert Chen, I. Flinn, M. Maris, O. O’Connor, L. D. Johnson, M. Irwin, Penka S. Petrova, R. Uger, E. Sievers +9 moresemanticscholar +1 more sourceTTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
, 2017 S. Ansell, I. Flinn, M. Maris, O. O’Connor, A. Lesokhin, A. Advani, M. Minden, M. Percival, L. D. Johnson, Tina Catalano, M. Irwin, Penka S. Petrova, R. Uger, E. Sievers, Robert Chen +14 moresemanticscholar +1 more sourceAbbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors
, 2017 S. Tahir, Morey L. Smith, L. Solomon, Haichao Zhang, John Xue, Yu Xiao, Dong Cheng, GR Buchanan, S. Morgan-Lappe, D. Phillips +9 moresemanticscholar +1 more sourceInitial clinical trial of a novel hemostat, TDM‐621, in the endoscopic treatments of the gastric tumors
Journal of Gastroenterology and Hepatology, 2014 Masashi Yoshida, Naoki Goto, M. Kawaguchi, H. Koyama, Junko Kuroda, T. Kitahora, H. Iwasaki, Shinji Suzuki, M. Kataoka, Fujii Takashi, M. Kitajima +10 moresemanticscholar +1 more sourceAbstract 2653: The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor
, 2017 E. Linderoth, S. Helke, V. Lee, Tapfuma Mutukura, Ml Wong, G. Lin, L. D. Johnson, X. Pang, Jeff Winston, Penka S. Petrova, R. Uger, N. N. Viller +11 moresemanticscholar +1 more source
